Highlights to be presented at Novo’s Capital Markets Day 2026
Novo Nordisk (NVO) is hosting a 2026 Capital Markets Day in London to update investors on its corporate strategy and strategic ambitions for 2030.
Rhea-AI Summary
Novo Nordisk (NVO) is hosting a 2026 Capital Markets Day in London to update investors on its corporate strategy and strategic ambitions for 2030.
Management presentations cover corporate and R&D strategy, therapy-area positioning, commercial strategy in the US and internationally, global manufacturing and supply, and financials. Strategic ambitions include launching more than five multi-blockbuster products by 2030 and targeting over 150 billion DKK in risk-adjusted pipeline sales in 2035. The company aims for at least five Phase 3 programmes in obesity and diabetes and at least five in other therapy areas, a 2026–2030 revenue CAGR in line with selected industry peers, the capacity to serve 10 times more people with obesity on oral GLP-1, service of more than 60 million patients globally by 2030, broadly stable operating margins and an attractive dividend per share.
Positive
- None.
Negative
- None.
Details
Market Reaction – NVO
Following this news, NVO has declined 6.16%, reflecting a notable negative market reaction. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $40.53. Trading volume is exceptionally heavy at 11.1x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bagsværd, Denmark, 21 September 2026 – Novo Nordisk is today hosting a Capital Markets Day (CMD) in London, where the company is providing an update to its Corporate strategy and strategic ambitions for 20301.
During the day, Novo senior management presentations will cover Corporate strategy, R&D strategy, where to play and how to win across therapy areas, Commercial strategy in the US and International Operations, Global Manufacturing & Supply and Financials.
Key highlights of the strategic ambitions for 20301 are:
Grow and diversify pipeline
- Launch >5 multi-blockbusters by 2030 and deliver >150 bDKK2 pipeline sales in 2035
- ≥5 Phase 3 programmes in obesity and diabetes3
- ≥5 Phase 3 programmes in other TAs3
Drive sustainable growth
- Deliver 2026-30 revenue CAGR in line with industry peers1
- Scale capacity to be able to serve 10x more people with obesity on oral GLP-1
- Serve >60m patients globally by 2030
Deliver attractive returns
- Maintain a broadly stable operating margin1
- Maintain an attractive dividend per share
All sessions of the CMD are webcast live, and a replay will be made available in the investor section of novonordisk.com. Presentation material from the CMD will also be available throughout the day in the investor section of novonordisk.com.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, approximately 66,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.
This press release may contain certain forward-looking statements relating to the operating, research & development, financial and sustainability performance and results of Novo and/or the industry in which it operates. By their very nature, forward-looking statements involve risks, uncertainties and assumptions, both general and specific, and actual results may differ materially from those contemplated, expressed or implied by any forward-looking statement. Please refer to: http://novonordisk.com/news-and-media/news-and-ir-materials/news-details/forward-looking-statement-cmd-2026.html for further information.
Contacts for further information
| Novo Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Novo Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com | Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
1 All ambitions are by 2030 from a 2026 baseline, they are inherently uncertain and do not constitute Novo’s financial outlook or guidance; revenue and margin ambitions are all based on adjusted metrics; CAGR: Compound annual growth rate; Industry peers: Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck & Co, Biogen, Pfizer, Bristol Myers Squibb
2 >150 bDKK ambition is risk-adjusted and includes current pipeline assets
3 Enter or complete, including new and current programmes; TA: Therapy areas
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can investors and other stakeholders follow Novo Nordisk’s 2026 Capital Markets Day?
All Capital Markets Day sessions are webcast live, and a replay will be made available in the investor section of novonordisk.com. Presentation materials from the event will also be accessible there throughout the day.
What key strategic ambition does Novo Nordisk have for its late-stage pipeline by 2030–2035?
The company aims to launch more than five multi-blockbuster products by 2030 and targets risk-adjusted pipeline sales of over 150 billion DKK in 2035, including current pipeline assets.
What are Novo Nordisk’s ambitions for Phase 3 development programmes by 2030?
Novo Nordisk targets at least five Phase 3 programmes in obesity and diabetes and at least five Phase 3 programmes in other therapy areas, including new and current programmes.
What growth and return ambitions does Novo Nordisk describe for 2026–2030?
The company aims to deliver a 2026–2030 revenue compound annual growth rate (CAGR) in line with a defined group of industry peers, maintain a broadly stable operating margin based on adjusted metrics, and maintain an attractive dividend per share. These ambitions are not described as financial outlook or guidance.
What capacity and patient reach targets does Novo Nordisk set for 2030?
Novo Nordisk plans to scale capacity so it is able to serve 10 times more people with obesity on oral GLP-1 and aims to serve more than 60 million patients globally by 2030.